Business
Enanta Pharmaceuticals Reports Financial Results for its Fiscal Third Quarter Ended June 30, 2020 with Webcast and Conference Call Today at 4:30 p.m. ET
Initiated Phase 1b Study of EDP-514 in Viremic HBV Patients and Resumed Phase 1b Study of EDP-514 in NUC-Suppressed HBV Patients; Preliminary Data Expected
About this update from Enanta Pharmaceuticals, Inc.
[{"type":"text","content":"\n\nInitiated Phase 1b Study of EDP-514 in Viremic HBV Patients and Resumed Phase 1b Study of EDP-514 in NUC-Suppressed HBV Patients; Preliminary Data Expected in 1H 2021 and 2Q 2021, Respectively\n\n\nPlans to Initiate Two Phase 2 Studies of EDP-938 in Pediatric and Adult Transplant Patients with RSV in 4Q 2020\n\n\nInitiated ARGON-2 Phase 2b Study of EDP-305 in Patients with NASH, On Track to Initiate Phase 1 Study of EDP-297 for NASH in 3Q 2020 \n\n\nRoyalty Revenue for the Quarter was $18.7 Million\n\n\nCash and Marketable Securities Totaled $435.4 Million at June 30, 2020\n\n\n WATERTOWN, Mass.--(BUSINESS WIRE)--\nEnanta Pharmaceuticals, Inc. (NASDAQ:ENTA), a clinical-stage biotechnology company dedicated to creating small molecule drugs for viral infections and liver diseases, today reported financial results for its fiscal third quarter ended June 30, 2020.\n\n\n“During the past quarter, Enanta made progress in our clinical development programs, laying the groundwork for several catalyst-rich quarters to come. Our virology programs, developed from years of antiviral drug discovery expertise, continue to advance with the initiation of our Phase 1b clinical trial in viremic HBV patients and the resumption of our Phase 1b study in HBV patients currently treated with nucleos(t)ide reverse transcriptase inhibitors, which was previously paused due to the COVID-19 pandemic,” said Jay R. Luly, Ph.D., President and Chief Executive Officer of Enanta Pharmaceuticals. “In addition, our Phase 2b RSVP trial in RSV is ongoing, and we are on schedule to initiate two additional studies for the condition, one in pediatric patients and a second in adult transplant patients, by year end. Finally, we are also excited about advancing our candidates in NASH this quarter, starting with the initiation of the ARGON-2 trial of EDP-305, our potent FXR agonist candidate, and the planned initiation later this quarter of the Phase 1 study of EDP-297, our highly potent and targeted follow-on FXR agonist.”\n\n\nFiscal Third Quarter Ended June 30, 2020 Financial Results\n\n\nTotal revenue of $18.7 million for the three months ended June 30, 2020 consisted of royalty revenue derived primarily from worldwide net sales of AbbVie’s hepatitis C virus (HCV) regimen MAVYRET®/MAVIRET®. For the three months ended June 30, 2019, total revenue was $44.4 million, whi...